T1	Participants 45 60	prostate cancer
T2	Participants 141 165	212 randomized patients.
T3	Participants 167 241	Two hundred and twelve patients treated for prostatic cancer grade I or II
T4	Participants 294 361	The patients were part of a multicentre study in the Stockholm area
